Dr. Rivero on Monocytic Differentiation in AML

Now Viewing

EP: 1.Dr. Rivero on Monocytic Differentiation in AML

EP: 2.Dr. Carraway on Next-Generation Sequencing in AML

EP: 3.Dr. Pollyea on the Role of Maintenance Therapy in AML

EP: 4.Genomics Guide Treatment, But Novel Agents Generate Excitement in AML and HR-MDS

Gustavo Rivero, MD, associate professor, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses evolving therapies for patients with acute myeloid leukemia (AML) with monocytic differentiation.

The current standard of care for patients with AML who are ineligible for intensive chemotherapy is the combination of a hypomethylating agent (HMA) and venetoclax (Venclexta), Rivero says. However, patients with monocytic differentiation often display inferior responses to this regimen, Rivero explains.

Recent evidence suggests that AML with monocytic differentiation can have lower BCL-2 expression and higher MCL-1 expression, potentially explaining their resistance to HMAs and venetoclax and serving as prognostic markers.

Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.